AI drug discovery company BenevolentAI stated on Monday that its AI-derived hypothesis for baricitinib has been approved for the treatment of COVID-19 based on the data of randomised clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
On 8 May 2020, the company launched a large scale randomised control trial in more than 1,000 patients to assess the efficacy and safety of baricitinib plus remdesivir versus remdesivir in hospitalised patients with COVID-19.
According to Eli Lilly, Baricitinib in combination with remdesivir achieved the primary endpoint of the study, which was a statistically significant reduction in the time to recovery for patients in comparison with remdesivir alone. The participant were well enough for hospital discharge and the patient either no longer required ventilation or ongoing medical care within the hospital, or was no longer hospitalised.
In addition, Lilly is conducting a Phase 3 randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib in hospitalised adults with COVID-19.
Baricitinib, which is approved for the treatment of rheumatoid arthritis and other diseases, is administered orally and has been used to treat COVID-19 patients in more than 14 clinical trials worldwide including the randomised clinical trials by the NIAID and Eli Lilly.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients